{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:19:30Z","timestamp":1757618370400,"version":"3.44.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00108-025-01918-0","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:44:50Z","timestamp":1749815090000},"page":"979-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gewichtsreduktion mit Inkretinmimetika\u00a0\u2013 Chancen und\u00a0Risiken","Weight reduction with incretin mimetics\u2014Opportunities and risks"],"prefix":"10.1007","volume":"66","author":[{"given":"Thomas J.","family":"Zech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kirchweger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"1918_CR1","doi-asserted-by":"publisher","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan\u00a0B, Ma\u00a0T, Ottaway\u00a0N, Muller\u00a0TD, Habegger\u00a0KM, Heppner\u00a0KM, Kirchner\u00a0H, Holland\u00a0J, Hembree\u00a0J, Raver\u00a0C, Lockie\u00a0SH, Smiley\u00a0DL, Gelfanov\u00a0V, Yang\u00a0B, Hofmann\u00a0S, Bruemmer\u00a0D, Drucker\u00a0DJ, Pfluger\u00a0PT, Perez-Tilve\u00a0D, Gidda\u00a0J, Vignati\u00a0L, Zhang\u00a0L, Hauptman\u00a0JB, Lau\u00a0M, Brecheisen\u00a0M, Uhles\u00a0S, Riboulet\u00a0W, Hainaut\u00a0E, Sebokova\u00a0E, Conde-Knape\u00a0K, Konkar\u00a0A, DiMarchi\u00a0RD, Tschop\u00a0MH (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151","journal-title":"Sci Transl Med"},{"key":"1918_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey\u00a0WT, Frias\u00a0JP, Jastreboff\u00a0AM, le Roux\u00a0CW, Sattar\u00a0N, Aizenberg\u00a0D, Mao\u00a0H, Zhang\u00a0S, Ahmad\u00a0NN, Bunck\u00a0MC, Benabbad\u00a0I, Zhang\u00a0XM, S.-. investigators (2023) Tirzepatide once weekly for the treatment of obesity in people with type\u00a02 diabetes (SURMOUNT-2): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase\u00a03\u00a0trial. Lancet 402:613\u2013626","journal-title":"Lancet"},{"key":"1918_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/dc24-0491","volume":"47","author":"SE Kahn","year":"2024","unstructured":"Kahn\u00a0SE, Deanfield\u00a0JE, Jeppesen\u00a0OK, Emerson\u00a0SS, Boesgaard\u00a0TW, Colhoun\u00a0HM, Kushner\u00a0RF, Lingvay\u00a0I, Burguera\u00a0B, Gajos\u00a0G, Horn\u00a0DB, Hramiak\u00a0IM, Jastreboff\u00a0AM, Kokkinos\u00a0A, Maeng\u00a0M, Matos\u00a0A, Tinahones\u00a0FJ, Lincoff\u00a0AM, Ryan\u00a0DH (2024) Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 47:1350\u20131359","journal-title":"Diabetes Care"},{"key":"1918_CR4","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.2337\/dc21-1785","volume":"45","author":"L Perreault","year":"2022","unstructured":"Perreault\u00a0L, Davies\u00a0M, Frias\u00a0JP, Laursen\u00a0PN, Lingvay\u00a0I, Machineni\u00a0S, Varbo\u00a0A, Wilding\u00a0JPH, Wallenstein\u00a0SOR, le Roux\u00a0CW (2022) Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4\u202fmg Among Participants With Prediabetes in the STEP Program. Diabetes Care 45:2396\u20132405","journal-title":"Diabetes Care"},{"key":"1918_CR5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, le Roux\u00a0CW, Stefanski\u00a0A, Aronne\u00a0LJ, Halpern\u00a0B, Wharton\u00a0S, Wilding\u00a0JPH, Perreault\u00a0L, Zhang\u00a0S, Battula\u00a0R, Bunck\u00a0MC, Ahmad\u00a0NN, Jouravskaya\u00a0I (2025) Tirzepatide for Obesity Treatment and Diabetes Prevention. N\u00a0Engl J Med 392:958\u2013971","journal-title":"N Engl J Med"},{"key":"1918_CR6","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"NM Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0NM, Abildstr\u00f8m\u00a0ZS, Barry\u00a0AB, Butler\u00a0J, Rasmussen\u00a0S, Davies\u00a0M, Hovingh\u00a0GK, Kitzman Dalane\u00a0W, Lindegaard\u00a0LM, M\u00f8ller\u00a0VD, Shah\u00a0JS, Treppendahl\u00a0BM, Verma\u00a0S, Abhayaratna\u00a0W, Fozia\u00a0ZA, Chopra\u00a0V, Ezekowitz\u00a0J, Fu\u00a0M, Ito\u00a0H, Lelonek\u00a0M, Melenovsky\u00a0V, Merkely\u00a0B, N\u00fa\u00f1ez\u00a0J, Perna\u00a0E, Schou\u00a0M, Senni\u00a0M, Sharma\u00a0K, Van der Meer\u00a0P, von Lewinski\u00a0D, Wolf\u00a0D, Mark\u00a0CP (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med 389:1069\u20131084","journal-title":"N Engl J Med"},{"key":"1918_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer\u00a0M, Zile\u00a0RM, Kramer\u00a0MC, Baum\u00a0JS, Litwin\u00a0ES, Menon\u00a0V, Ge\u00a0J, Weerakkody\u00a0JG, Ou\u00a0Y, Bunck\u00a0CM, Hurt\u00a0CK, Murakami\u00a0M, Barry\u00a0AB (2025) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N\u00a0Engl J Med 392:427\u2013437","journal-title":"N Engl J Med"},{"key":"1918_CR8","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang\u00a0L, Wang\u00a0Q, Li\u00a0L, Kaelber\u00a0DC, Xu\u00a0R (2025) Glucagon-like peptide\u20111 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J\u00a0Natl Cancer Inst 117:476\u2013485","journal-title":"J Natl Cancer Inst"},{"key":"1918_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin\u00a0J, Gouverneur\u00a0A, Penichon\u00a0M, Mathieu\u00a0C, Garrel\u00a0R, Hillaire-Buys\u00a0D, Pariente\u00a0A, Faillie\u00a0JL (2023) GLP\u20111 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 46:384\u2013390","journal-title":"Diabetes Care"},{"key":"1918_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan\u00a0AG, Blind\u00a0E, Dunder\u00a0K, de Graeff\u00a0PA, Hummer\u00a0BT, Bourcier\u00a0T, Rosebraugh\u00a0C (2014) Pancreatic safety of incretin-based drugs\u2014FDA and EMA assessment. N\u00a0Engl J Med 370:794\u2013797","journal-title":"N Engl J Med"},{"key":"1918_CR11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies\u00a0M, Pieber\u00a0TR, Hartoft-Nielsen\u00a0ML, Hansen\u00a0OKH, Jabbour\u00a0S, Rosenstock\u00a0J (2017) Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type\u00a02 Diabetes: A\u00a0Randomized Clinical Trial. JAMA 318:1460\u20131470","journal-title":"JAMA"},{"key":"1918_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","volume":"159","author":"S Sen","year":"2024","unstructured":"Sen\u00a0S, Potnuru\u00a0PP, Hernandez\u00a0N, Goehl\u00a0C, Praestholm\u00a0C, Sridhar\u00a0S, Nwokolo\u00a0OO (2024) Glucagon-Like Peptide\u20111 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surg 159:660\u2013667","journal-title":"JAMA Surg"},{"key":"1918_CR13","first-page":"52","volume":"41","author":"E Herron","year":"2024","unstructured":"Herron\u00a0E, Cencetti\u00a0J, Matis\u00a0J (2024) Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a\u00a0Glucagon-like Peptide\u20111 Agonist. Fed Pract 41:52\u201356","journal-title":"Fed Pract"},{"key":"1918_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Bain\u00a0SC, Consoli\u00a0A, Eliaschewitz\u00a0FG, Jodar\u00a0E, Leiter\u00a0LA, Lingvay\u00a0I, Rosenstock\u00a0J, Seufert\u00a0J, Warren\u00a0ML, Woo\u00a0V, Hansen\u00a0O, Holst\u00a0AG, Pettersson\u00a0J, Vilsboll\u00a0T, S.-. Investigators (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type\u00a02 Diabetes. N\u00a0Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"1918_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway\u00a0JT, Shah\u00a0MP, Hathaway\u00a0DB, Zekavat\u00a0SM, Krasniqi\u00a0D, Gittinger\u00a0JW Jr., Cestari\u00a0D, Mallery\u00a0R, Abbasi\u00a0B, Bouffard\u00a0M, Chwalisz\u00a0BK, Estrela\u00a0T, Rizzo\u00a0JF 3rd (2024) Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 142:732\u2013739","journal-title":"JAMA Ophthalmol"},{"key":"1918_CR16","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","volume":"11","author":"S Christensen","year":"2024","unstructured":"Christensen\u00a0S, Robinson\u00a0K, Thomas\u00a0S, Williams\u00a0DR (2024) Dietary intake by patients taking GLP\u20111 and dual GIP\/GLP\u20111 receptor agonists: A\u00a0narrative review and discussion of research needs. Obes Pillars 11:100121","journal-title":"Obes Pillars"},{"key":"1918_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding\u00a0JPH, Batterham\u00a0RL, Davies\u00a0M, Van Gaal\u00a0LF, Kandler\u00a0K, Konakli\u00a0K, Lingvay\u00a0I, McGowan\u00a0BM, Oral\u00a0TK, Rosenstock\u00a0J, Wadden\u00a0TA, Wharton\u00a0S, Yokote\u00a0K, Kushner\u00a0RF, Group\u00a0SS (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1\u00a0trial extension. Diabetes Obes Metab 24:1553\u20131564","journal-title":"Diabetes Obes Metab"},{"key":"1918_CR18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff\u00a0AM, le Roux\u00a0CW, Stefanski\u00a0A, Aronne\u00a0LJ, Halpern\u00a0B, Wharton\u00a0S, Wilding\u00a0JPH, Perreault\u00a0L, Zhang\u00a0S, Battula\u00a0R, Bunck\u00a0MC, Ahmad\u00a0NN, Jouravskaya\u00a0I, S.-. Investigators (2025) Tirzepatide for Obesity Treatment and Diabetes Prevention. N\u00a0Engl J Med 392:958\u2013971","journal-title":"N Engl J Med"},{"key":"1918_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer\u00a0X, Astrup\u00a0A, Fujioka\u00a0K, Greenway\u00a0F, Halpern\u00a0A, Krempf\u00a0M, Lau\u00a0DC, le Roux\u00a0CW, Ortiz\u00a0RV, Jensen\u00a0CB, Wilding\u00a0JP, Obesity\u00a0S, N.N.S.G. Prediabetes (2015) A\u00a0Randomized, Controlled Trial of 3.0\u202fmg of Liraglutide in Weight Management. N\u00a0Engl J Med 373:11\u201322","journal-title":"N Engl J Med"},{"key":"1918_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding\u00a0JPH, Batterham\u00a0RL, Calanna\u00a0S, Davies\u00a0M, Van Gaal\u00a0LF, Lingvay\u00a0I, McGowan\u00a0BM, Rosenstock\u00a0J, Tran\u00a0MTD, Wadden\u00a0TA, Wharton\u00a0S, Yokote\u00a0K, Zeuthen\u00a0N, Kushner\u00a0RF, Group\u00a0SS (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N\u00a0Engl J Med 384:989\u20131002","journal-title":"N Engl J Med"},{"key":"1918_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff\u00a0AM, Aronne\u00a0LJ, Ahmad\u00a0NN, Wharton\u00a0S, Connery\u00a0L, Alves\u00a0B, Kiyosue\u00a0A, Zhang\u00a0S, Liu\u00a0B, Bunck\u00a0MC, Stefanski\u00a0A, S.-. Investigators (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N\u00a0Engl J Med 387:205\u2013216","journal-title":"N Engl J Med"},{"key":"1918_CR22","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","volume":"73","author":"H Moll","year":"2024","unstructured":"Moll\u00a0H, Frey\u00a0E, Gerber\u00a0P, Geidl\u00a0B, Kaufmann\u00a0M, Braun\u00a0J, Beuschlein\u00a0F, Puhan\u00a0MA, Yebyo\u00a0HG (2024) GLP\u20111 receptor agonists for weight reduction in people living with obesity but without diabetes: a\u00a0living benefit-harm modelling study. EClinicalMedicine 73:102661","journal-title":"EClinicalMedicine"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01918-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:25:45Z","timestamp":1757186745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01918-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"12 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.J.\u00a0Zech h\u00e4lt Aktien von Eli Lilly und Novo Nordisk. B.\u00a0Kirchweger und R.\u00a0F\u00fcrst geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}